104 results on '"Van Laere, Koen"'
Search Results
2. PSMA PET/CT and PET/MRI in primary staging of prostate cancer and its effect on patient management
3. Prospective comparison of [18F]AlF-NOTA-octreotide PET/MRI to [68Ga]Ga-DOTATATE PET/CT in neuroendocrine tumor patients
4. Not all black colons on [18F]FDG PET are due to metformin
5. Simultaneous 18F-FDG PET/MR metabolic and structural changes in visual snow syndrome and diagnostic use
6. [18F] MFBG PET imaging: biodistribution, pharmacokinetics, and comparison with [123I] MIBG in neural crest tumour patients
7. Association of Alzheimer’s disease polygenic risk scores with amyloid accumulation in cognitively intact older adults
8. Biodistribution and dosimetry in human healthy volunteers of the PET radioligands [11C]CHDI-00485180-R and [11C]CHDI-00485626, designed for quantification of cerebral aggregated mutant huntingtin
9. Long-term test-retest of cerebral [18F]MK-6240 binding and longitudinal evaluation of extracerebral tracer uptake in healthy controls and amnestic MCI patients
10. Spatial decrease of synaptic density in amnestic mild cognitive impairment follows the tau build-up pattern
11. Correction to: Effects of chronic voluntary alcohol consumption on PDE10A availability: a longitudinal behavioral and [18F]JNJ42259152 PET study in rats
12. Value of [68Ga]Ga-somatostatin receptor PET/CT in the grading of pulmonary neuroendocrine (carcinoid) tumours and the detection of disseminated disease: single-centre pathology-based analysis and review of the literature
13. Classification of 18F-Flutemetamol scans in cognitively normal older adults using machine learning trained with neuropathology as ground truth
14. Regional glucose metabolic decreases with ageing are associated with microstructural white matter changes: a simultaneous PET/MR study
15. Prospective comparison of simultaneous [68Ga]Ga-PSMA-11 PET/MR versus PET/CT in patients with biochemically recurrent prostate cancer
16. Interhemispheric metabolic asymmetries in patients with anti-NMDA receptor encephalitis
17. Minimally invasive quantification of cerebral P2X7R occupancy using dynamic [18F]JNJ-64413739 PET and MRA-driven image derived input function
18. Lower regional gray matter volume in the absence of higher cortical amyloid burden in late-life depression
19. Effects of chronic voluntary alcohol consumption on PDE10A availability: a longitudinal behavioral and [18F]JNJ42259152 PET study in rats
20. Parameters predicting [18F]PSMA-1007 scan positivity and type and number of detected lesions in patients with biochemical recurrence of prostate cancer
21. Human biodistribution and dosimetry of [11C]-UCB-J, a PET radiotracer for imaging synaptic density
22. Baseline cognition is the best predictor of 4-year cognitive change in cognitively intact older adults
23. Predictive value of metabolic and perfusion changes outside the seizure onset zone for postoperative outcome in patients with refractory focal epilepsy
24. The Leuven late life depression (L3D) study: PET-MRI biomarkers of pathological brain ageing in late-life depression: study protocol
25. A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate
26. STAT2 signaling restricts viral dissemination but drives severe pneumonia in SARS-CoV-2 infected hamsters
27. Brain metabolic changes across King’s stages in amyotrophic lateral sclerosis: a 18F-2-fluoro-2-deoxy-d-glucose-positron emission tomography study
28. Peptide receptor radionuclide therapy controls inappropriate calcitriol secretion in a pancreatic neuro-endocrine tumor: a case report
29. Clinical validation of the novel HDAC6 radiotracer [18F]EKZ-001 in the human brain
30. [18F]AlF-NOTA-octreotide PET imaging: biodistribution, dosimetry and first comparison with [68Ga]Ga-DOTATATE in neuroendocrine tumour patients
31. Long-term Ashtanga yoga practice decreases medial temporal and brainstem glucose metabolism in relation to years of experience
32. EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0
33. Improved resolution and sensitivity of [18F]MFBG PET compared with [123I]MIBG SPECT in a patient with a norepinephrine transporter–expressing tumour
34. Combined brain and spinal FDG PET allows differentiation between ALS and ALS mimics
35. Direct prospective comparison of 18F-FDG PET and arterial spin labelling MR using simultaneous PET/MR in patients referred for diagnosis of dementia
36. Binding of [18F]AV1451 in post mortem brain slices of semantic variant primary progressive aphasia patients
37. Quantification and discriminative power of 18F-FE-PE2I PET in patients with Parkinson’s disease
38. Identifying a glucose metabolic brain pattern in an adeno-associated viral vector based rat model for Parkinson’s disease using 18F-FDG PET imaging
39. Al18F-NOTA-octreotide: first comparison with 68Ga-DOTATATE in a neuroendocrine tumour patient
40. Regional changes in the type 1 cannabinoid receptor are associated with cognitive dysfunction in Parkinson’s disease
41. [11C]JNJ54173717, a novel P2X7 receptor radioligand as marker for neuroinflammation: human biodistribution, dosimetry, brain kinetic modelling and quantification of brain P2X7 receptors in patients with Parkinson’s disease and healthy volunteers
42. Validation of Parametric Methods for [11C]UCB-J PET Imaging Using Subcortical White Matter as Reference Tissue
43. Preclinical Safety Evaluation and Human Dosimetry of [18F]MK-6240, a Novel PET Tracer for Imaging Neurofibrillary Tangles
44. Volume-of-interest-based supervised cluster analysis for pseudo-reference region selection in [18F]DPA-714 PET imaging of the rat brain
45. Glucose metabolic brain patterns to discriminate amyotrophic lateral sclerosis from Parkinson plus syndromes
46. Quantifying SV2A density and drug occupancy in the human brain using [11C]UCB-J PET imaging and subcortical white matter as reference tissue
47. Single-word comprehension deficits in the nonfluent variant of primary progressive aphasia
48. Distinct [18F]THK5351 binding patterns in primary progressive aphasia variants
49. On the optimal z-score threshold for SISCOM analysis to localize the ictal onset zone
50. Mixed response on regorafenib treatment for GIST (gastro-intestinal stromal tumor) according to 18F–FDG-PET/CT
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.